Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of U.S. Patent No. 12,492,179 on December 29, 2025, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
The patent claims compositions and treatment methods for novel, potentially neuroplastogenic and non‑hallucinogenic molecules, expands the company’s pipeline of patent‑protected candidates, and provides composition‑of‑matter protection intended to strengthen licensing and partnership prospects in neuropsychiatric, neurological, and addiction disorders.
ENvue Medical (NASDAQ: ENVB) announced on December 15, 2025 that David Johnson has been appointed Chairman of the Board. Johnson brings more than 30 years of healthcare leadership and board experience, including roles guiding Advanced Medical Balloons through acquisition and prior executive positions at ConvaTec and others.
The company said its 510(k) FDA-cleared feeding-tube placement system is in clinical use across 38 US hospitals, and management plans to increase hospital adoption in 2026 while pursuing additional 510(k) clearances to expand into neonatal and pediatric markets.
Enveric Biosciences (NASDAQ: ENVB) closed the exercise of outstanding warrants for an aggregate of 426,390 shares, raising approximately $3.1 million in gross proceeds prior to fees and expenses. The exercised warrants issued in Feb and Sep 2025 had original strike prices of $36.00 and $10.98, respectively, and were exercised at a reduced $7.05 per share.
In connection with the cash exercises and a $0.125 per-warrant payment (aggregate $106,597.50 included in gross proceeds), the company issued new unregistered series E warrants (5-year term) and series F warrants (18-month term), both exercisable immediately at $7.05. H.C. Wainwright acted as placement agent. Net proceeds are intended for product development, working capital, and general corporate purposes. The company will file a resale registration statement covering shares issuable upon exercise of the new warrants.
Enveric Biosciences (NASDAQ: ENVB) announced definitive agreements for the immediate exercise of outstanding warrants to purchase up to 426,390 shares at a reduced exercise price of $7.05 per share, generating expected gross proceeds of approximately $3.1 million (before fees and expenses).
In connection with the exercises, the company will issue new unregistered Series E and Series F warrants (each to purchase up to 426,390 shares) with exercise price $7.05; Series E expires five years after the resale registration effective date and Series F expires 18 months after that date. The offering is expected to close on or about December 12, 2025.
Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on December 9, 2025 for a patent application covering its EVM301 Series of molecules titled “N-heterocycle substituted tryptamine derivatives and methods of using.”
The allowance will add to Enveric’s patent portfolio, covering compositions and methods of use for additional neuroplastogenic, non-hallucinogenic molecules and is described as reinforcing intellectual property around lead asset EB-003, which the company says is designed to engage 5-HT2A and 5-HT1B receptors to provide fast-acting antidepressant and anxiolytic effects while minimizing hallucinogenic effects.
Enveric Biosciences (NASDAQ: ENVB) will present and participate in a panel at the Sachs Associates 9th Annual Neuroscience Innovation Forum on January 11, 2026 during J.P. Morgan Week in San Francisco and will attend Biotech Showcase 2026 from January 12–14, 2026 at the Hilton San Francisco Union Square. Management plans one-on-one meetings with registered investors and potential partners to highlight the company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
Event details include the panel titled "Meeting the Promise of Psychedelics Panel: Expected Trends for 2026" at the Marines’ Memorial Club and registration links for both events.
Enveric Biosciences (NASDAQ: ENVB) received a Notice of Allowance from the USPTO on November 26, 2025 for a U.S. patent application covering its EVM401 Series of molecules.
The allowed application, entitled "Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives," will be the fourth U.S. patent for the EVM401 program and is described as broadening claims to additional potential non-hallucinogenic neuroplastogenic molecules aimed at neuropsychiatric and addiction disorders. The company said the allowance, once issued as a patent, expands its intellectual property estate and strengthens its pipeline of next-generation, non-hallucinogenic neuroplastogens.
Enveric Biosciences (NASDAQ: ENVB) reported Q3 2025 results and operational progress toward an IND for lead candidate EB-003. Key clinical and CMC milestones include completion of pre-IND dose range finding studies establishing a maximum tolerated dose, positive preclinical PTSD model data (significant reduction in context-induced freezing, p < 0.05), receipt of an FDA written response to a pre-IND meeting request, and production of a 1-kilogram pharmaceutically compatible salt batch to support IND-enabling work.
Corporate actions: issued and pursued patents, hired outside counsel to defend U.S. Patent No. 12,138,276, relocated headquarters to Cambridge, MA, completed warrant exercises generating approximately $2.2 million gross, completed a reverse 1-for-12 stock split after a Nasdaq bid-price deficiency, and reported Q3 net loss of $3.4 million with $3.8 million cash as of September 30, 2025.
Enveric Biosciences (NASDAQ: ENVB) will effect a 1-for-12 reverse stock split, effective at 8:00 a.m. New York time on October 28, 2025. The company received a Nasdaq delisting determination on October 22, 2025 related to minimum bid price, and the Board approved the 1-for-12 ratio under a previously authorized 1-for-5 to 1-for-50 range.
The reverse split will convert every 12 pre-split shares into one post-split share, reduce outstanding common stock from 6,219,568 to approximately 518,297 shares, and apply proportional adjustments to equity awards and warrants. Fractional shares will be rounded up to whole shares.
Enveric Biosciences (NASDAQ: ENVB) announced issuance of its 23rd U.S. patent from the USPTO, U.S. Patent No. 12,428,408, titled “Fused Heterocyclic Mescaline Derivatives.”
The patent covers a unique series of neuroplastogenic small-molecule compounds designed to target key serotonin receptors and promote neuroplasticity, expanding Enveric’s intellectual property footprint and supporting potential pipeline expansion for treatments of psychiatric and neurological disorders.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
